91 related articles for article (PubMed ID: 10498879)
1. Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector.
Adams JM; Harris AW; Strasser A; Ogilvy S; Cory S
Oncogene; 1999 Sep; 18(38):5268-77. PubMed ID: 10498879
[TBL] [Abstract][Full Text] [Related]
2. The transgenic window on lymphoid malignancy.
Adams JM; Harris AW; Vaux DL; Alexander WS; Rosenbaum H; Klinken SP; Strasser A; Bath ML; McNeall J; Cory S
Princess Takamatsu Symp; 1989; 20():297-309. PubMed ID: 2518688
[TBL] [Abstract][Full Text] [Related]
3. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.
Strasser A; Harris AW; Bath ML; Cory S
Nature; 1990 Nov; 348(6299):331-3. PubMed ID: 2250704
[TBL] [Abstract][Full Text] [Related]
4. Regulatory elements of the vav gene drive transgene expression in hematopoietic stem cells from adult mice.
Almarza E; Segovia JC; Guenechea G; Gómez SG; Ramírez A; Bueren JA
Exp Hematol; 2004 Apr; 32(4):360-4. PubMed ID: 15050746
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells.
Vaux DL; Cory S; Adams JM
Nature; 1988 Sep; 335(6189):440-2. PubMed ID: 3262202
[TBL] [Abstract][Full Text] [Related]
6. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC.
Smith DP; Bath ML; Harris AW; Cory S
Oncogene; 2005 May; 24(22):3544-53. PubMed ID: 15688022
[TBL] [Abstract][Full Text] [Related]
7. Vav promoter-tTA conditional transgene expression system for hematopoietic cells drives high level expression in developing B and T cells.
Kim WI; Wiesner SM; Largaespada DA
Exp Hematol; 2007 Aug; 35(8):1231-9. PubMed ID: 17560009
[TBL] [Abstract][Full Text] [Related]
8. A human immunoglobulin gene reduces the incidence of lymphomas in c-Myc-bearing transgenic mice.
Nussenzweig MC; Schmidt EV; Shaw AC; Sinn E; Campos-Torres J; Mathey-Prevot B; Pattengale PK; Leder P
Nature; 1988 Dec; 336(6198):446-50. PubMed ID: 3143076
[TBL] [Abstract][Full Text] [Related]
9. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
10. High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector.
Gao Z; Golob J; Tanavde VM; Civin CI; Hawley RG; Cheng L
Stem Cells; 2001; 19(3):247-59. PubMed ID: 11359950
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic potential of cyclin E in T-cell lymphomagenesis in transgenic mice: evidence for cooperation between cyclin E and Ras but not Myc.
Karsunky H; Geisen C; Schmidt T; Haas K; Zevnik B; Gau E; Möröy T
Oncogene; 1999 Dec; 18(54):7816-24. PubMed ID: 10618723
[TBL] [Abstract][Full Text] [Related]
12. Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors.
Sirven A; Ravet E; Charneau P; Zennou V; Coulombel L; Guétard D; Pflumio F; Dubart-Kupperschmitt A
Mol Ther; 2001 Apr; 3(4):438-48. PubMed ID: 11319904
[TBL] [Abstract][Full Text] [Related]
13. Progress toward the genetic treatment of the beta-thalassemias.
Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
[TBL] [Abstract][Full Text] [Related]
14. RCAS/SCL-TVA animal model allows targeted delivery of polyoma middle T oncogene to vascular endothelial progenitors in vivo and results in hemangioma development.
Sausville J; Molinolo AA; Cheng X; Frampton J; Takebe N; Gutkind JS; Feldman RA
Clin Cancer Res; 2008 Jun; 14(12):3948-55. PubMed ID: 18559617
[TBL] [Abstract][Full Text] [Related]
15. VavCre transgenic mice: a tool for mutagenesis in hematopoietic and endothelial lineages.
Georgiades P; Ogilvy S; Duval H; Licence DR; Charnock-Jones DS; Smith SK; Print CG
Genesis; 2002 Dec; 34(4):251-6. PubMed ID: 12434335
[TBL] [Abstract][Full Text] [Related]
16. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.
Gabril MY; Onita T; Ji PG; Sakai H; Chan FL; Koropatnick J; Chin JL; Moussa M; Xuan JW
Gene Ther; 2002 Dec; 9(23):1589-99. PubMed ID: 12424611
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein Ibalpha promoter drives megakaryocytic lineage-restricted expression after hematopoietic stem cell transduction using a self-inactivating lentiviral vector.
Lavenu-Bombled C; Izac B; Legrand F; Cambot M; Vigier A; Massé JM; Dubart-Kupperschmitt A
Stem Cells; 2007 Jun; 25(6):1571-7. PubMed ID: 17379771
[TBL] [Abstract][Full Text] [Related]
18. Uncovering MYC's full oncogenic potential in the hematopoietic system.
Janz S
Oncogene; 2005 May; 24(22):3541-3. PubMed ID: 15782131
[TBL] [Abstract][Full Text] [Related]
19. Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model.
Avilés Mendoza GJ; Seidel NE; Otsu M; Anderson SM; Simon-Stoos K; Herrera A; Hoogstraten-Miller S; Malech HL; Candotti F; Puck JM; Bodine DM
Mol Ther; 2001 Apr; 3(4):565-73. PubMed ID: 11319919
[TBL] [Abstract][Full Text] [Related]
20. The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.
Duan H; Heckman CA; Boxer LM
Oncogene; 2007 Apr; 26(18):2635-41. PubMed ID: 17043638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
